Informations bibliographiques
Ligne directriceWHO updated recommendations on HIV clinical management: recommendations for a public health approach
Année de publication2025
Institution émettriceWorld Health Organization
Recommandation
Mise à jour
Use of darunavir/ritonavir and other protease inhibitors in HIV treatment. Darunavir/ritonavir (DRV/r) is the preferred boosted protease inhibitor option for antiretroviral treatment.
Recommandé en faveur
Forte
Certitude des données probantes
Modérée